Effexor Sales Growth Far Outpacing Antidepressant Class, Wyeth Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Venlafaxine sales "value and volume" are growing two to three times the market rate for antidepressants, Exec VP Poussot says. Growth has been spurred by international sales; Effexor sales volume rose 2% in the U.S. during the first half of 2005.
You may also be interested in...
Generic Effexor XR Could Hit Antidepressant Market By June 2008
Wyeth and Teva settle patent infringement suit; Teva believes it holds 180-day exclusivity for generic extended-release venlafaxine.
Generic Effexor XR Could Hit Antidepressant Market By June 2008
Wyeth and Teva settle patent infringement suit; Teva believes it holds 180-day exclusivity for generic extended-release venlafaxine.
Antidepressant Market Will Remain Flat In Face Of Adult Suicidality Concerns, Forest Says
The impact of media attention on the adult suicide issue will be “hard to predict,” President & COO Goodman says. Forest expects FDA action on a Namenda supplemental NDA for mild-to-moderate Alzheimer’s in the next few weeks.